Impact of Clinical Variables on cfDNA Fragmentomic Signatures and Their Potential as Confounders in Cancer Detection
Physiological factors such as liver enzyme levels and age can significantly alter cfDNA fragmentomic profiles, generating patterns that resemble lung cancer-associated signals. These results highlight the importance of incorporating strategies to mitigate nonmalignant variability when developing cfDNA-based liquid biopsy assays, to ensure their accuracy, specificity, and clinical applicability.
Authors
- Junnam Lee (ORCID: https://orcid.org/0000-0002-4356-9091)
- Min‐Jung Kwon (ORCID: https://orcid.org/0000-0002-2372-0700)
- Byeong‐Ho Jeong (ORCID: https://orcid.org/0000-0002-3124-1718)
- Eun‐Hae Cho (ORCID: https://orcid.org/0000-0003-3056-0001)
- Jin Mo Ahn (ORCID: https://orcid.org/0000-0002-9073-9911)
- Chang‐Seok Ki (ORCID: https://orcid.org/0000-0001-7679-8731)
- Tae-Rim Lee (ORCID: https://orcid.org/0000-0003-0684-6552)
- Eun Hye Cho (ORCID: https://orcid.org/0000-0002-9328-9389)
Institutions
- Samsung Medical Center (KR)
- Genome and Company (South Korea) (KR)
- Kangbuk Samsung Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Clinical Chemistry
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1093/clinchem/hvaf163
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94